Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
1. The planned acquisition of Spectronic Medical AB's software, which uses AI to convert MR images into synthetic CT images for radiation treatment planning
2. FDA 510(k) clearance of MR Contour DL, an AI model for organs at risk (OAR) segmentation, capable of segmenting 37 organs in head-neck and pelvic regions
3. Updates to the Intelligent Radiation Therapy (iRT) solution, featuring new third-party AI integration capabilities and MR imaging workflows
These innovations aim to optimize oncology care workflow, enable shorter treatment timelines, and deliver more precise radiation therapy. The company's solutions address the growing global cancer burden, which accounts for nearly ten million deaths annually according to WHO.
GE HealthCare reported strong Q1 2025 financial results with 3% revenue growth to $4.8 billion and 4% organic revenue growth. Net income margin improved to 11.8% from 8.0% year-over-year, while diluted EPS increased to $1.23 from $0.81.
The company showed growth across all segments, with Pharmaceutical Diagnostics leading at 8% organic growth. Notable achievements include the successful launch of Flyrcado injection in the U.S. and completion of the Nihon Medi-Physics acquisition.
However, GE HealthCare updated its 2025 guidance to reflect tariff impacts, reducing its adjusted EPS forecast to $3.90-$4.10 from $4.61-$4.75. The Board authorized a $1 billion share repurchase program, demonstrating confidence in long-term prospects despite challenges.
Book-to-bill ratio was strong at 1.09x, with total orders increasing 10% organically. Free cash flow decreased to $98 million from $274 million in the previous year.
GE HealthCare (Nasdaq: GEHC) has announced its management team's participation in two major upcoming investor conferences in 2025. The company will present at the Bank of America Securities Healthcare Conference in Las Vegas on May 13, 2025, at 10:00 am CT, and the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10, 2025, at 9:00 am CT.
Investors and interested parties can access webcasts of both presentations through the company's investor relations website at investor.gehealthcare.com/news-events/events during the scheduled times.
GE HealthCare (GEHC) will showcase its latest breast health technology advancements at the 2025 Society of Breast Imaging Symposium in Colorado Springs. The company is featuring several key innovations:
The Pristina Via™ mammography system offers streamlined workflows with zero-click acquisition, no wait time between exposures, and faster DBT image-to-image cycle times. The company will distribute DeepHealth's SmartMammo™, an AI-powered solution for breast cancer screening, now commercially available in the U.S.
Additional innovations include the Invenia™ ABUS Premium, the first FDA-approved breast ultrasound for dense breast detection, showing a 35.7% increase in cancer detection when used with mammography. The company also presents SenoBright™ HD and SerenaBright™, the first FDA-cleared Contrast Enhanced Mammography and CEM biopsy solutions.
GE HealthCare (GEHC) has scheduled the release of its first quarter 2025 financial results for Wednesday, April 30, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 AM Eastern Time / 7:30 AM Central Time on the same day.
The earnings release, accompanying financial materials, and webcast replay will be accessible through the company's Investor Relations website at investor.gehealthcare.com.
Cincinnati Children's and GE HealthCare (GEHC) have announced a groundbreaking strategic research collaboration to establish the first pediatric Care Innovation Hub nationwide. The partnership aims to advance pediatric medical imaging innovation across multiple modalities including MRI, CT, molecular imaging, and ultrasound.
The collaboration brings together Cincinnati Children's clinical expertise with GE HealthCare's medical technology capabilities to develop pediatric-focused imaging technologies. Key focus areas include: developing high-density MR coil arrays specifically sized for children, creating AI algorithms for ultrasound, evaluating new PET and SPECT imaging technologies, and optimizing CT workflows for pediatric patients.
This initiative represents a new model for combining resources and talent to accelerate innovation in pediatric imaging. The findings and technologies developed through this partnership are intended to benefit pediatric care providers globally, with the goal of improving clinical outcomes and patient care delivery.
GE HealthCare (Nasdaq: GEHC) has appointed Jeannette Bankes as president and CEO of Patient Care Solutions, effective May 1, 2025. Bankes, who brings three decades of global healthcare industry experience, joins from Alcon where she served as senior vice president and president of Global Franchises, overseeing product development and commercialization across surgical, vision care, and ocular health businesses.
The appointment was announced by Peter Arduini, president and CEO of GE HealthCare, who emphasized Bankes' proven leadership and extensive experience in publicly traded healthcare companies. She previously held senior leadership positions at Boston Scientific and Merck. Bankes will be based in Waukesha, Wisconsin, replacing Tom Westrick, who is retiring after 20+ years with the company. Westrick will remain until May 31, 2025, to ensure a smooth transition.
GE HealthCare (GEHC) has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics (NMP), giving it full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures.
Kevin O'Neill, President & CEO of GE HealthCare's Pharmaceutical Diagnostics segment, will also become President of NMP. The company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter. The acquisition positions NMP to enhance patient access to next-generation radiopharmaceuticals in Japan, which is projected to become a leader in the $7 billion molecular imaging global market.
GE HealthCare (GEHC) has unveiled the Revolution™ Vibe CT system, featuring Unlimited One-Beat Cardiac imaging technology. The system addresses the growing global cardiovascular disease (CVD) challenge, projected to cause over 23 million deaths by 2030.
The new CT system delivers consistent, high-quality cardiac images even in challenging cases like atrial fibrillation and heavily calcified coronaries. Key features include ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and AI-powered Effortless Workflow solutions. Clinical evaluation showed the system's one-step decision tree workflow reduced exam time by 50% and saved four minutes of radiologists' time per study.
The Revolution Vibe enables facilities to expand cardiac CT capacity while improving operational efficiency. The system supports CCTA (Cardiac CT Angiography) as a first-line investigation tool for suspected coronary artery disease, aligning with NICE recommendations and recent Medicare reimbursement rate increases.